On December 17, 2024, Percheron Therapeutics announced topline six-month results from the Company’s ongoing international phase IIb randomised, placebo-controlled trial of avicursen (ATL1102) in non-ambulant boys with Duchenne muscular dystrophy (DMD).
To read their full press release, please click here.
